Radiopharm Theranostics (ASX:RAD) has responded to an ASX compliance letter concerning their disclosure practices. The inquiry addressed the timing of information release related to their product RAD 402 and a subsequent rise in share price.
Radiopharm Theranostics addressed an ASX inquiry about compliance with Listing Rule 3.1 after a significant share price increase. The company became aware of the material information on December 5th, 2024, and released it on December 10th, following internal deliberations. They confirmed the information's price sensitivity and their compliance with disclosure rules. The announcement regarding RAD 402's preclinical dataset was deemed impactful. Radiopharm reiterated their commitment to transparency and regulatory adherence, emphasizing the importance of timely disclosures for market integrity.
Radiopharm Theranostics confirmed that they had assessed the information as price-sensitive and had released it promptly once it was sufficiently definite.